Evidence map›Paper›PMID 20385003›Full record

ArticleBMC immunology2010

Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients.

Vanessa Deschoolmeester, Marc Baay, Eric Van Marck, Joost Weyler, Peter Vermeulen, Filip Lardon, Jan B Vermorken

3 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in BMC immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 119 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 3 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02574598 phase2completednot on this mapstarted 2016, after this paper: background citation

A Randomized Crossover, Phase II Clinical Trial of MK-3475 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Non-Small Cell Lung Cancer (NSCLC) Previously Treated.

TypeinterventionalSponsorInstituto Nacional de Cancerologia de MexicoRan2016 to 2020Enrolled78ConditionsCarcinoma, Non-Small-Cell LungArmsMK-3475, Docetaxel
NCT02591615 phase2completednot on this mapstarted 2016, after this paper: background citation

Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition With Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients With Chemotherapy Naive Stage IV Non-small Cell Lung Cancer

TypeinterventionalSponsorAlliance Foundation Trials, LLC.Ran2016 to 2020Enrolled91ConditionsNon-Small Cell Lung CancerArmsMK-3475, Carboplatin, Paclitaxel, Pemetrexed
NCT02906332 phase2terminatednot on this mapstarted 2016, after this paper: background citation

A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma

TypeinterventionalSponsorHackensack Meridian HealthRan2016 to 2022Enrolled12ConditionsMultiple MyelomaArmsPembrolizumab, Lenalidomide, Dexamethasone
3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 3 syntheses or guidelines pooled it, 233 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Tumour-infiltrating CD8British journal of cancer · 2019
    Trial
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Vanessa DeschoolmeesterLaboratory of Cancer Research and Clinical Oncology, Department of Medical Oncology, University of Antwerp (UA/UZA), Wilrijk, Belgium. vanessa.deschoolmeester@ua.ac.be
Marc Baay
Eric Van Marck
Joost Weyler
Peter Vermeulen
Filip Lardon
Jan B Vermorken
University of Antwerp · BEAntwerp University Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is growing evidence that both local and systemic inflammatory responses play an important role in the progression of a variety of solid tumors. Colorectal cancer results from the cumulative effect of sequential genetic alterations, leading to the expression of tumor associated antigens possibly inducing a cellular anti-tumor immune response. It is well recognized that cytotoxic lymphocytes constitute one of the most important effector mechanisms of anti-tumor-immunity. However, their potential prognostic influence in colorectal cancer remains controversial. Aim of the study was to examine infiltration of CD3+ and CD8+ lymphocytes in colorectal cancer and their prognostic potential.Two-hundred-fifteen colorectal cancer cases, previously analyzed for microsatellite instability (MSI), were selected for immunohistochemical detection of CD3+, CD8+ infiltration and the expression of granzyme B. Prognostic relevance was assessed by survival analysis.

resultsStrong correlations were found between the infiltration of lymphocytes and several clinicopathological variables. Survival analysis revealed that intra-epithelial infiltration of CD3+ and CD8+ T lymphocytes and stromal infiltration of CD3+ lymphocytes had a major impact on the patients' overall survival in the univariate analysis, however independent of their association with MSI-status. In addition, it was also demonstrated that there was an important disease specific survival advantage for patients with microsatellite stable (MSS) tumors containing intraepithelial CD8+ tumor infiltrating lymphocytes. When samples were analyzed for colon cancer and rectal cancer separately, the results of the overall population were confirmed in colon cancer only. When entered into a multiple Cox regression analysis adjusting for other possible important confounding factors, the strong impact of lymphocyte infiltration on overall survival was not maintained. Only early stage and young age (borderline significant for overall population only) were associated with a better overall survival (early disease with disease-free survival also).

conclusionsIn conclusion our results suggest a role for infiltrating CD3+ and CD8+ T lymphocytes in colorectal cancer whereby tumor infiltration could reflect a general principle of antitumor immunity, irrespective of the MSI-status.

Indexed as

AgedBiomarkers, TumorCD8-Positive T-LymphocytesColorectal NeoplasmsDisease-Free SurvivalFemaleHumansImmunohistochemistryKaplan-Meier EstimateLymphocytes, Tumor-InfiltratingMaleMicrosatellite InstabilityMiddle AgedBiomarkers, Tumor

Identifiers

PMID20385003
PMCPMC2864219
OpenAlexW2036717657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.